INTRODUCTION

Mucin 1 (MUC1), a heterodimeric transmembrane glycoprotein, is one of the mucin family members that form protective mucous barriers on epithelial surfaces. The MUC1 gene encodes a single polypeptide chain that is auto-proteolytically cleaved to generate two subunits, the N-terminal subunit (MUC1-N) and the C-terminal subunit (MUC1-C), which form a stable complex. Dysregulated expression of MUC1 has been associated with the progression of many types of epithelial tumors due to its myriad oncogenic functions. In addition to its protective and lubricative functions for many types of epithelial tumors due to its myriad oncogenic functions. In addition to its protective and lubricative functions for many types of epithelial tumors due to its myriad oncogenic functions.
ILK regulates the protein stability of MUC1-C
H-L Huang et al.

RESULTS

ILK mediated the effect of IL-6 on MUC1-C overexpression concurrently with STAT3 activation

We measured MUC1-C expression in normal pancreatic cells (NPCs) versus different pancreatic cancer cell lines by western blot analysis. While NPCs, BxPC-3, Panc-1 and MiaPaCa2 cells lacked appreciable MUC1-C expression, AsPC-1 and SW1990 cells exhibited low and high abundance of MUC1-C, respectively (Figure 1a). Consistent with the reported effect of IL-6 on MUC1-C overexpression in breast and lung cancer cells,22,33 exposure of AsPC-1 cells to IL-6 led to parallel increases in STAT3 phosphorylation and the expression of MUC1-C, and, to a lesser extent, ILK (Figure 1b). The ability of IL-6 to stimulate MUC1-C expression was confirmed by the stable expression of IL-6 in AsPC-1 (AsPC-1IL-6) cells (Figure 1b, right panel) and in IL-6-treated SW1990 cells (Figure 1c, left). This phenomenon, however, was not noted in MUC1-deficient Panc-1 cells (Figure 1c, right).

As MUC1 is a STAT3 target gene,20–22,33 it follows that STAT3 activation played a crucial role in regulating MUC1-C expression in AsPC-1 cells. STAT3 depletion by two different shRNAs (#886 and #887) was effective in reducing the expression of endogenous MUC1-C as well as in blocking IL-6-induced MUC1-C upregulation (Figure 1d). In parallel, we also examined the effect of shRNA-mediated ILK knockdown on MUC1 expression in AsPC-1 cells treated with exogenous IL-6 or stably expressing IL-6. It is noteworthy that ILK depletion was equally as effective as STAT3 depletion in abolishing IL-6-induced MUC1-C overexpression (Figure 2a). Similarly, shRNA-mediated knockdown of E2F1, a transcription factor that regulates ILK gene expression,32,34 led to parallel decreases in MUC1-C levels in AsPC-1 cells (Figure 2b). In order to rule out the possibility that the inhibitory effect of ILK knockdown on MUC1-C expression might be associated with its ability to interfere with STAT3 signaling, we fractionated cellular and nuclear fractions to determine ILK knockdown affect the phosphorylation and/or cellular distribution of STAT3 in response to IL-6. However, this ILK depletion did not cause appreciable changes in the phosphorylation or cellular distribution of STAT3 in response to IL-6. Moreover, although silencing of ILK caused a sharp decrease in MUC1-C abundance, the mRNA expression of MUC1-C remained unaltered (Figure 2d). Furthermore, ILK knockdown in untreated AsPC-1 and SW1990 cells caused downregulation of endogenous MUC1-C expression without affecting MUC1 mRNA levels (Figure 2e). We also found ILK knockdown to have the same effect on MUC1-C expression in two other cancer cell lines, including DU-145 prostate cancer and MDA-MB-231 breast cancer cells (Supplementary Figure S1), revealing that the suppressive...
The effect of ILK depletion on MUC1-C expression was not a cell line-specific phenomenon. Together, these findings demonstrated the unique ability of ILK to regulate MUC1-C expression independently of MUC1 gene expression.

The mechanistic link between ILK and MUC1-C expression was further confirmed by the ability of ectopically expressed constitutively active ILK to increase MUC1-C expression in AsPC-1 cells (Figure 3a, left). This upregulation, however, did not occur when the kinase-dead form of ILK was overexpressed (right), suggesting that the kinase activity of ILK was required to mediate the effect on MUC1-C expression. Pursuant to this finding, we used an ILK kinase inhibitor, T315,32,35 as a proof of concept to verify the functional role of ILK. Consistent with the consequences of ILK depletion, exposure of AsPC-1, AsPC-1IL-6 and SW1990 cells to T315 suppressed the expression of endogenous MUC1-C and inhibited IL-6-induced MUC1-C overexpression (Figure 3b). Furthermore, T315 (2 μM) was effective in abrogating the effect of ILK overexpression on MUC1-C expression (Figure 3c). Quantitative real-time PCR (qRT-PCR) analysis indicated that MUC1 mRNA expression levels remained largely unaltered by T315 in AsPC-1 and SW1990 cells, with the exception of T315 at 3 μM in AsPC-1 cells (Figure 3d), which might be attributed to extensive cell death. Nevertheless, overexpression of ILK-CA failed to increase MUC1-C levels in STAT3-depleted AsPC-1 cells, suggesting that ILK acted downstream of STAT3 in regulating MUC1-C expression (Figure 3e).

In addition to IL-6, hypoxia also induces MUC1-C accumulation in pancreatic cancer cells, in turn driving hypoxia-driven...
ILK regulates the protein stability of MUC1-C
H-L Huang et al

**Figure 3.** Evidence that ILK kinase activity is involved in regulating MUC1-C expression. (a) Ectopic expression of GFP-tagged constitutively active ILK (ILK-CA), but not GFP-tagged kinase-dead ILK (ILK-KD), mimics the effect of IL-6 on MUC1-C upregulation in AsPC-1 cells. (b) Suppressive effect of T315 on (left) MUC1-C expression in AsPC-1 and AsPC-1IL-6 cells, and (right) endogenous and IL-6-induced upregulation of MUC1-C expression in SW1990 cells. SW1990 cells were exposed to IL-6 (50 ng/ml) and T315 (2 μM) concurrently for 24 h. (c) T315 (2 μM) was effective in suppressing wild-type ILK (ILK-WT)-induced overexpression of MUC1-C in AsPC-1 cells. (d) qRT-PCR analysis of the dose-dependent effect of T315 versus control on MUC1 mRNA expression in AsPC-1 and SW1990 cells (means ± s.e., n = 3). (e) Lack of effect of the ectopic effect of GFP-tagged ILK-CA on STAT3 knockdown-induced depletion of MUC1-C expression in AsPC-1 cells. In western blot analysis, data shown are representative of at least three independent experiments.

Angiogenesis. Consistent with this report, subjecting AsPC-1 cells to hypoxic conditions led to MUC1-C upregulation in a time-dependent manner, which could be reversed to the basal level by T315 treatment (Supplementary Figure S2).

ILK inhibition promotes ubiquitin-dependent MUC1-C degradation. On the basis of the qRT-PCR evidence that genetic knockdown or pharmacological inhibition of ILK did not alter MUC1 mRNA levels, we hypothesized that the effect of ILK inhibition on MUC1-C downregulation was attributable to proteasomal degradation, which was supported by the following studies. First, we used pulse chase assays to analyze the effect of ILK inhibition on MUC1-C protein stability. In the presence of cycloheximide, shRNA-mediated depletion of ILK (Figure 4a, upper) or T315 (lower) promoted the clearance of MUC1-C, relative to the DMSO control, in both AsPC-1 and SW1990 cells. Second, the proteasome inhibitor MG-132 protected AsPC-1 cells against the suppressive effect of T315 on MUC1-C expression (Figure 4b). Third, we used co-immunoprecipitation (Co-IP) analysis to investigate the effect of ILK inhibition on MUC1-C ubiquitination. In AsPC-1 and SW1990 cells ectopically expressing HA-tagged ubiquitin (HA-Ub), the ability of T315 (2 μM) or genetic ILK knockdown to suppress MUC1-C expression was attributable to increased MUC1-C ubiquitination (Figures 4c and d). Together, these data reveal the pivotal role of ILK in the regulation of MUC1-C protein stability.

PKCδ is involved in mediating the ubiquitin-dependent degradation of MUC1-C in response to ILK inhibition. As ubiquitin-dependent protein degradation is preceded by phosphorylation, we evaluated the effect of T315 on MUC1-C phosphorylation via Co-IP. As shown, concentration-dependent downregulation of MUC1-C expression was associated with parallel increases in Ser/Thr phosphorylation in both AsPC-1 and SW1990 cells (Figure 5a). Although MUC1-C is known to be phosphorylated by multiple kinases, including glycogen synthase kinase (GSK)3β and PKCδ, the identity of the kinase responsible for its degradation remained undefined. Thus, we analyzed a panel of kinase inhibitors for the ability to block T315-induced suppression of MUC1-C expression in AsPC-1 cells, including the pan-PKC inhibitor GF-109203X, the casein kinase (CK)2α inhibitor DMAT, the c-Jun N-terminal kinase (JNK) inhibitor SP-600125, the p38 MAP kinase inhibitor SB-203580, the IkB kinase (IKK)α inhibitor Bay-11-7082 and the GSK3β inhibitor SB-216763. It is noteworthy that GF-109203X, when used alone, increased MUC1-C accumulation, and was able to partially protect cells from the suppressive effect of T315, and, to a greater extent, ILK knockdown on MUC1-C expression (Figures 5b and c). In contrast, none of the other kinase inhibitors examined exhibited the ability to rescue cells from T315-mediated MUC1-C downregulation (Figure 5b).

To identify the PKC isozyme responsible for MUC1-C degradation, we selectively depleted individual isozymes (α, β, γ, δ, ε) with two different shRNAs each and assessed the effects on T315-facilitated suppression of MUC1-C expression in AsPC-1 cells. Among these five isozymes, only knockdown of PKCδ resulted in the desired protective effect on MUC1-C repression, while silencing of the other isozymes had no significant appreciable protection (Figure 6a). The intermediary role of PKCδ in mediating this cellular response was further confirmed by the following experiments in AsPC-1 cells. First, Co-IP analysis revealed that ILK knockdown-mediated phosphorylation of MUC1-C was accompanied by a parallel increase in the binding of PKCδ to MUC1-C. This increased binding, however, was not noted with the negative control PKCα (Figure 6b). Second, shRNA-mediated depletion of ILK led to increased phosphorylation of PKCδ at the activation loop Thr-507, while PKCα phosphorylation remained unaltered (Figure 6c, left). Conversely, overexpression of ILK in AsPC-1 cells resulted in the reversal of the above changes in MUC1-C expression and Thr-507-PKCδ phosphorylation (Figure 6c, right). Taken together, these data suggest that PKCδ is regulated by ILK inhibition, as well as involved in ILK-mediated ubiquitin-dependent MUC1-C degradation.
Pursuant to a recent report that PPARγ acts as an E3 ligase responsible for MUC1-C degradation independent of its transcriptional activity in HT-29 and MCF-7 cells,25 we investigated the potential involvement of PPARγ in T315-induced MUC1-C repression by examining whether siRNA-mediated knockdown of PPARγ could protect cells from this drug-induced MUC1-C degradation. However, silencing of PPARγ alone caused suppression of MUC1-C expression, and, together with T315, completely depleted MUC1-C in AsPC-1 and SW1990 cells (Figure 7a). Together, these data argued against the involvement of PPARγ as an E3 ligase in facilitating T315-mediated MUC1-C degradation in these pancreatic cancer cells.

To identify the E3 ligase responsible for ILK inhibition-induced MUC1-C degradation, we turned our attention to Fbw7 (F-box and WD repeat domain-containing 7; aka, Fbxw7) and β-TrCP in light of their tumor-suppressive activities in facilitating the degradation of oncogenic proteins.40 Accordingly, we analyzed the effects on MUC1-C ubiquitination in AsPC-1 and/or SW1990 cells. Cells ectopically expressing HA-ubiquitin (HA-Ub) were treated with (c) 2 μM T315 for 18 h followed by co-treatment with 1 μM MG-132 for an additional 6 h or (d) 1 μM MG-132 for 6 h. Equal amounts of cell protein lysates were immunoprecipitated with MUC1-C antibody and protein A/G agarose beads followed by immunoblotting with Ub and MUC1-C antibodies. Data shown are representative of at least three independent experiments.

Figure 4. ILK inhibition facilitated the suppression of MUC1-C expression through ubiquitin-dependent proteasomal degradation. (a) T315 (upper) or shRNA-mediated ILK knockdown (lower) decreased the protein stability of MUC1-C in AsPC-1 and SW1900 cells. Cells were co-treated with T315 (2 μM) and cycloheximide (100 μg/ml) or ILK-depleted cells were treated with cycloheximide (100 μg/ml) for the indicated time intervals. (b) The proteasome inhibitor MG-132 protects AsPC-1 and SW1990 cells from T315-mediated MUC1-C degradation. Cells were treated with 1 μM MG-132 and 2 μM T315, individually or in combination, versus vehicle control for 24 h. (c, d) ILK inhibition via T315 treatment or shRNA-mediated ILK depletion facilitates MUC1-C ubiquitination in AsPC-1 and/or SW1990 cells. Cells ectopically expressing HA-ubiquitin (HA-Ub) were treated with (c) 2 μM T315 for 18 h followed by co-treatment with 1 μM MG-132 for an additional 6 h or (d) 1 μM MG-132 for 6 h. Equal amounts of cell protein lysates were immunoprecipitated with MUC1-C antibody and protein A/G agarose beads followed by immunoblotting with Ub and MUC1-C antibodies. Data shown are representative of at least three independent experiments.

Oncogenesis (2017), 1 – 10
induced downregulation of MUC1-C expression. Together, these data suggest the potential involvement of \( \beta \)-TrCP in mediating the ubiquitin-dependent degradation of MUC1-C, which warrants further investigation.

**In vivo mechanistic validation**

To confirm our findings of the functional role of ILK in mediating PKC\( \delta \)-dependent MUC1-C degradation in vivo, we examined the expression levels of relevant biomarkers in T315-treated AsPC-1 tumors after 21 days of treatment. These tumor samples were previously prepared in our recent study of the KRAS–ILK signaling loop, in which daily oral administration of T315 at 50 mg/kg inhibited AsPC-1 xenograft tumor growth by 51\% (described in the Supplementary Figure S2 of cited reference;\(^32\) http://www.nature.com/onc/journal/v35/n30/extref/onc2015458x1.pdf). Consistent with the in vitro finding, T315 significantly downregulated ILK and MUC1-C expression and increased PKC\( \delta \) phosphorylation in AsPC-1 tumors in nude mice (\( P < 0.05; \) Figure 8).

**DISCUSSION**

Substantial evidence indicates that MUC1-C signaling is upregulated in the course of tumor progression to promote an aggressive phenotype, in part, through cross talk with the tumor microenvironment.\(^5,6,8\) For example, a number of stress signals, including IL-6 and hypoxia, have been reported to induce the accumulation of MUC1-C to drive epithelial-mesenchymal transition (EMT) and angiogenesis.\(^22,36\) Multiple mechanisms at different molecular levels have been reported to regulate MUC1-C overexpression,\(^5,15–19\) among which the MUC1-C–STAT3 autoregulatory loop in breast cancer cells is especially noteworthy.\(^22\) Here we report a post-transcriptional mechanism, in which ILK acts by blocking PKC\( \delta \)-mediated protein degradation of MUC1-C. From a mechanistic perspective, the cooperative interplay between STAT3 and ILK would facilitate an immediate cellular response to IL-6 and other stress signals to upregulate MUC1-C expression at both transcriptional and post-transcriptional levels. As overexpression of ILK could not rescue the effect of STAT3 depletion on MUC1-C expression, it is likely that ILK acts downstream of STAT3 in MUC1-C regulation. Nevertheless, genetic knockdown or pharmacological inhibition of ILK caused depleted MUC1-C expression in IL-6-treated pancreatic cancer cells, indicating that ILK is required to sustain STAT3-induced MUC1 upregulation by maintaining its stability.

Moreover, in light of the ability of ILK to regulate oncogenic KRAS signaling,\(^22\) the present study also provides a mechanistic link between KRAS and MUC1-C. As MUC1-C has been reported to confer KRAS independence in mutant KRAS lung cancer cells,\(^41\) it warrants investigation whether targeting ILK can mitigate the effect of MUC1-C overexpression on KRAS independence.

Evidence suggests that T315-mediated MUC1-C degradation was facilitated by PKC\( \delta \)-mediated phosphorylation (Figure 6). This finding is consistent with the report that PKC\( \delta \) binds and phosphorylates MUC1-C on Thr-41 at the TDRSPY motif, which attenuates the interaction between MUC1-C and \( \beta \)-catenin.\(^39\) As PKC\( \delta \) is activated in response to oxidative or genotoxic stress to trigger apoptotic responses,\(^42–44\) we hypothesize that activation of PKC\( \delta \) by genetic depletion of ILK or T315 was attributable to...
reactive oxygen species (ROS) production and/or DNA damage, which is currently under investigation.

In contrast to the reported function of PPARγ as the E3 ligase responsible for MUC1-C degradation independent of its transcriptional activity in HT-29 and MCF-7 cells, our data refute this mechanistic link, as PPARγ depletion reduced endogenous MUC1-C expression and could not protect cells from T315-induced depletion of MUC1-C. This discrepancy might be attributable to differences in cell lines and cellular contexts between these two studies. In the present study, we obtained evidence that β-TrCP might be involved in ILK depletion-induced MUC1-C degradation. This has prompted further confirmation and is under investigation. In summary, because ILK is activated in response to IL-6 and other environmental signals, the unique ability of ILK to regulate MUC1-C stability, in conjunction with STAT3-activated MUC1 gene expression, enables pancreatic cancer cells to interact with stress signals in the tumor microenvironment, such as IL-6 and hypoxia.

Figure 6. PKCδ is involved in facilitating T315 and ILK knockdown-mediated MUC1 phosphorylation and degradation. (a) Effects of shRNA-mediated selective depletion of PKC isoforms α, β, γ, δ and ε (two different shRNAs each) on T315-mediated MUC1-C downregulation. Selective PKC isoform-depleted cells were treated with T315 at the indicated concentrations for 24 h. (b) Co-IP analysis of the effect of shRNA-mediated ILK knockdown (left) and T315 (2 μM) treatment for 24 h (right) on MUC1-C phosphorylation and binding with PKCδ in AsPC-1 cells. PKCα was used as a negative control. Equal amounts of cell protein lysates were immunoprecipitated with MUC1-C antibody and protein A/G agarose beads followed by immunoblotting with p-Ser/Thr, PKCα, PKCδ and MUC1-C antibodies. (c) ILK negatively regulates PKCδ activation. Effects of shRNA-mediated knockdown (left) and ectopic expression of ILK (right) on PKCδ and/or PKCα phosphorylation. AsPC-1 cells were transiently transfected with Flag-WT-ILK for 48 h (right). Quantification was done by using ImageJ. Double bands shown in ILK and Flag were quantified separately and summed up together to get fold change compared to the control group. Data shown are representative of at least three independent experiments.
recent report that ILK controls the expression of oncogenic KRAS through a regulatory loop, underscores the pivotal role of ILK in promoting pancreatic cancer progression.

MATERIALS AND METHODS

Cell line, culture and reagents

Non-malignant human primary pancreatic cells (NPC) were purchased from Applied Biological Materials (Richmond, BC, Canada) and cultured in Prigrow 1 medium. AsPC-1, BxPC-3, Panc-1, MIA PaCa-2 and SW1990 pancreatic cancer cells, DU-145 prostate cancer cells, and MDA-MB-231 breast cancer cells were purchased from American Type Culture Collection (Manassas, VA, USA). AsPC-1, BxPC-3, Panc-1, SW1990 and DU-145 cells were cultured in RPMI 1640 medium, and MIA PaCa-2 and MDA-MB-231 cells were cultured in DMEM medium, supplemented with penicillin-streptomycin and 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA). Cells were cultured at 37 °C in a humified incubator containing 5% CO2. In hypoxia incubation, cells were cultured in hypoxia chamber (Proxx 110, Biospherix, Parish, NY, USA), flushed with 1% O2, 5% CO2 and 94% N2 at 37°C for the indicated time. Cells were recently authenticated by STR profiling and tested to confirm mycoplasma free. The ILK inhibitor T315 was synthesized in our laboratory as described previously. MG-132, SP-600125, SB-203580 and SB-216763 were purchased from Sigma-Aldrich (St Louis, MO, USA), and Bay-11-7082, cycloheximide and GF-109203X were from Calbiochem (San Diego, CA, USA). Antibodies for various proteins were from the following sources: ILK, Flag, STAT3, p-Tyr-705 STAT3, CREB, α-tubulin, Cell Signaling Technology (Danvers, MA, USA); ILK-C, β-TrCP, Thermo Fisher Scientific (Fremont, CA, USA); β-actin, MP Biomedicalals (Irvine, CA, USA); p-Ser/Thr, Fb7, Abcam, (Cambridge, MA, USA); ubiquitin, PKCα, p-Ser-657 PKCα, PKCBII, PKCβ, p-Thr-507-PKCδ, PKCε, PKCy, PPARγ, Santa Cruz Biologicals (Santa Cruz, CA, USA); rabbit anti-mouse IgG-HRP conjugates, goat anti-rabbit IgG-HRP conjugates, goat anti-rabbit hamster HRP conjugates, Jackson ImmunoResearch Laboratories (West Grove, PA, USA). Specific catalog numbers for each antibody are listed in Supplementary Table S1.

AsPC-1IL-6 stable clone selection

AsPC-1 cells were seeded in a 6-cm dish and transiently transfected with the pCMV-IL-6 plasmid. After 2 days, cells were expanded into ten 10-cm dishes and incubated with fresh culture medium containing G418 until colonies grew. Each single colony was then trypsinized using a cloning cylinder and expanded. IL-6 secretion into culture medium by cell colonies was analyzed by the IL-6 DuoSet ELISA kit (R&D, Minneapolis, MN, USA) according to the manufacturer’s instructions. One clone that produced the optimal amount of IL-6 in culture medium (550 ng/ml versus nil for parental AsPC-1 cells), designated as AsPC-1IL-6, was used in this study.

Transient transfection and immunoblotting

Cells were transfected with plasmids or siRNAs using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s instructions. pCMV-IL-6, Flag-tagged ILK-WT and GFP-tagged ILK (ILK-CA and ILK-KD) plasmids were generated as previously described. Other plasmids, shRNA and siRNA used in this study and their sources were: pcDNA3.1, Addgene (Cambridge, MA, USA); ILK siRNA (#6202), Cell Signaling Technology (Beverly, MA, USA); E2F1 shRNA, PPARγ siRNA, Santa Cruz Biologicals; Fb7 siRNA and β-TrCP siRNA, OriGene Technologies Inc. (Rockville, MD, USA). Immunoblotting and densitometric analysis were performed as previously described.

Lentiviral preparation and transfection

Lentiviral plasmids were cotransfected with the third Generation Packaging Systems (pMDLgp/RRE, #12251; pRSV-Rev, #12253; pMD2.G #12299) (Addgene) in 293T cells following a standard calcium phosphate transfection procedure. Viral particles were collected for transfection of target cells, followed by puromycin selection for 1 week to generate stable cell lines. The following lentiviral plasmids were obtained from Academia Sinica (Taipei, Taiwan): pLAS.Void (negative control), shILK (#0968), shSTAT3 (886, 887), shPKCα (#3511, #6909), shPKCBII (#3117, #5381), shPKCδ (#1180, #2640), shPKCc (#0844, #0848) and shPKCy (#0693, #2326).

Cellular fractionation

The following buffers were used for nuclear fractionation: harvest buffer (10 mM, 50 mM NaCl, 0.5 mM sucrose, 0.1 mM EDTA, 0.5% Triton X-100); buffer A (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1 mM MgCl2, 1% NP-40). Immediately before use, the following was added to each buffer: 2 mM sodium orthovanadate, 5 mM NaF, 1 mM sodium pyrophosphate, 2.5 mM glycerol phosphate, 1 mM DTT, 1 mM PMSF and protease inhibitor.
After the indicated treatment, cells were collected and resuspended in cold harvest buffer with 5 min incubation on ice. Cells were centrifuged at 3000 rpm for 10 min and supernatant was collected and centrifuged at 14,000 rpm for 15 min. The supernatants were collected as cytoplasmic proteins and membrane proteins. The pellet was washed using buffer A and resuspended in buffer C. The resuspended pellet was vortexed at high speed for 30 s and incubated on ice for 10 min three times. After centrifugation at 13,000 rpm for 15 min, the supernatant was collected as nuclear proteins.

qRT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen) and reverse-transcribed to cDNA using the iScript cDNA synthesis kit (Bio-Rad; Hercules, CA, USA). For qRT-PCR, cDNA was amplified in iQ SYBR Green Supermix (Bio-Rad) and detected with the Bio-Rad CFX96 RT-PCR detection system. Relative gene expression was normalized to GAPDH and calculated by using the 2^[-ΔΔCT] method. The primer sequences were: MUC1, forward: 5'-ACCTACATTCTATAGGACGAG-3', reverse: 5'-GGTTTGCTAAGAGAGCTG-3'; GAPDH; forward: 5'-AGGGGTCTACATGGCAACTGCT-3', reverse: 5'-CGACACATTTGTCAGCTCA-3'.

Co-IP analysis
Cells were lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100) containing phosphatase and protease inhibitor mixture on ice for 30 min. After centrifugation at 13,000 rpm for 15 min, the supernatant was stored at 4 °C for use as input, and the pellet was resuspended in cold lysis buffer with 5 min incubation on ice. Cells were centrifuged at 13,000 rpm for 15 min, and the supernatants were incubated with 20 μl protein A/G-sepharose beads at 4 °C for 2 h. The immunocomplexes were washed with lysis buffer, resuspended in 2 x sample buffer, and then subjected to immunostaining.

Statistical analysis
Each experiment was performed at least three times. Student’s t-test was performed using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA) to compare the mean of each group with that of the control group in experiments. P-values less than 0.05 were considered significant (*P < 0.05, **P < 0.01, ***P < 0.001).

CONFLICT OF INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENTS
This work was supported by Grant # MOST 105-2321-B-001-064 from the Team of Cancer Research Program of the Ministry of Science and Technology, Taiwan, the Lucius A Wing Endowed Chair Fund at The Ohio State University Medical Center (CSC) and a predoctoral fellowship from the Graduate Student Study Abroad Program, National Science Council, Taiwan (H-LH).

REFERENCES
1 Hanisch FG, Muller S. MUC1: the polymorphic appearance of a human mucin. Glycobiology 2000; 10: 439–449.
2 Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009; 9: 874–885.
3 Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med 2014; 20: 332–342.
4 Hattrup CL, Guilder SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 2008; 70: 431–457.
5 Hrom TM, Schroeder JA. MUC1 and metastatic cancer: expression, function and therapeutic targeting. Cell Adh Migr 2013; 7: 187–198.
6 Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene 2013; 32: 1073–1081.
7 Singh PK, Hollingsworth MA. Cell surface-associated mucins in signal transduction. Trends Cell Biol 2006; 16: 467–476.
8 Kufe DW. Functional targeting of the MUC1 oncogene in human cancers. Cancer Biol Ther 2009; 8: 1197–1203.
9 Mehla K, Singh PK. MUC1: a novel metabolic master regulator. Biochim Biophys Acta 2014; 1845: 126–135.
10 Schroeder JA, Masri AA, Adrice MC, Tessier JC, Kotlarczyk KL, Thompson MC et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004; 23: 5739–5747.
11 Bitter BG, Mendl I, Huerta CL, Sands B, Knowlton W, Chang A et al. Intracellular MUC1 peptides inhibit cancer progression. Clin Cancer Res 2009; 15: 100–109.
12 Kharbanda A, Rajabi H, Jin C, Tachioka J, Kikuchi E, Wong KK et al. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells. Clin Cancer Res 2014; 20: 5423–5434.
13 Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T et al. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009; 69: 3133–3141.
14 Rajabi H, Ahmad R, Jin C, Joshi MD, Goyal M, Alam M et al. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate 2012; 72: 1659–1668.
15 Jin C, Rajabi H, Rodrigo CM, Porco JA Jr, Kufe D. Targeting the eff4A4 RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene 2013; 32: 2179–2188.
16 Lagow EL, Carson DD. Synergistic stimulation of MUC1 expression in normal breast epithelia and breast cancer cells by interferon-gamma and tumor necrosis factor-alpha. J Cell Biochem 2002; 86: 759–772.
17 Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, Kufe D. Mucin 1 oncoprotein expression is suppressed by the mir-125b oncomir. Genes Cancer 2010; 1: 62–68.
18 Yamada N, Nishida Y, Tsutsuihama H, Hamada T, Goto M, Higashi M et al. MUC1 expression is regulated by DNA methylation and histone H3 lysine 9 modification in cancer cells. Cancer Res 2008; 68: 2708–2717.
19 Zaretsky JZ, Sarid R, Aylon Y, Mittelman LA, Wreschner DH, Keydar I. Analysis of the promoter of the MUC1 gene overexpressed in breast cancer. FEBS Lett 1999; 461: 189–195.
20 Gaemers IC, Vos HL, Volders HH, van der Valk SW, Hilkens J. A stat-responsive element in the promoter of the epialisin/MUC1 gene is involved in its over-expression in carcinoma cells. Mol Biol Cell 2004; 15: 9390–9400.
21 Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B et al. MUC1-C oncoprotein promotes STAT3 activation in an autioductive regulatory loop. Sci Signal 2011; 4: ra9.
22 Shalom-Barak T, Nicholas JM, Wang Y, Zhang X, Ong ES, Young TH et al. Peroxisome proliferator-activated receptor gamma controls MUC1 transcription in trophoblasts. Mol Cell Biol 2004; 24: 10661–10669.
23 Wang P, Damrajar N, Brayman MJ, Carson DD. Peroxisome proliferator-activated receptor gamma activation inhibits prostate-stimulated human MUC1 expression. Mol Endocrinol 2010; 24: 1368–1379.
24 Hou Y, Gao J, Xu H, Xu Y, Zhang Z, Xu Q et al. PPARgamma E3 ubiquitin ligase regulates MUC1-C oncoprotein stability. Oncogene 2014; 33: 5619–5625.
25 Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010; 70: 378–387.
26 Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005; 5: 51–63.
27 Hannigan GE, McDonald PC, Walsh MP, Dedhar S. Integrin-linked kinase: not so ‘pseudostatic’ after all. Oncogene 2011; 30: 4375–4385.
28 McDonald PC, Fielding AB, Dedhar S. Integrin-linked kinase–essential roles in physiology and cancer biology. J Cell Sci 2008; 121: 3121–3132.
29 Yau CY, Wheeler JJ, Sutton KL, Hedley DW. Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FAKR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts. Cancer Res 2005; 65: 1497–1504.
30 Sawai H, Okaeda Y, Funahashi H, Matsuo Y, Takahashi Y, Takeyama H et al. Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival. Oncogene 2006; 25: 3237–3246.
31 Chu PC, Yang MC, Kulp SK, Salunke SB, Himmel LE, Fang CS et al. Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells. Oncogene 2016; 35: 3897–3908.
32 Li YY, Hsieh LL, Tang RP, Liao SK, Yeh KY. Macrophage-derived interleukin-6 up-regulates MUC1, but down-regulates MUC2 expression in the human colon carcinoma cell line. Cell Immunol 2001; 209: 9–26.
33 Hsu EC, Kulp SK, Huang HL, Tu HJ, Salunke SB, Sullivan NJ et al. Function of integrin-linked kinase in modulating the stemness of IL-6-abundant breast cancer cells by regulating gamma-secretase-mediated notch1 activation in caveole. Neoplasia 2015; 17: 497–508.
ILK regulates the protein stability of MUC1-C
H-L Huang et al

Oncogenesis (2017), 1 – 10

35 Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK et al. Identification and characterization of a novel integrin-linked kinase inhibitor. J Med Chem 2011; **54**: 6364–6374.
36 Kitamoto S, Yokoyama S, Higashi M, Yamada N, Takao S, Yonezawa S. MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors. Oncogene 2013; **32**: 4614–4621.
37 Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; **6**: 369–381.
38 Li Y, Bharti A, Chen D, Gong J, Kufe D. Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol 1998; **18**: 7216–7224.
39 Ren J, Li Y, Kufe D. Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 2002; **277**: 17616–17622.
40 Lau AW, Fukushima H, Wei W. The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci 2012; **17**: 2197–2212.
41 Kharbanda A, Rajabi H, Jin C, Alam M, Wong KK, Kufe D. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells. Oncotarget 2014; **5**: 8893–8905.
42 Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM, Chen CS. Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIalpha degradation in hepatocellular carcinoma cells. Hepatology 2011; **53**: 148–159.
43 Liu H, Lu ZG, Miki Y, Yoshida K. Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol 2007; **27**: 8480–8491.
44 Yamaguchi T, Miki Y, Yoshida K. Protein kinase C delta activates IkappaB-kinase alpha to induce the p53 tumor suppressor in response to oxidative stress. Cell Signal 2007; **19**: 2088–2097.
45 Chou CC, Chuang HC, Salunke SB, Kulp SK, Chen CS. A novel HIF-1alpha-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1alpha expression and epithelial-mesenchymal transition in cancer cells. Oncotarget 2015; **6**: 8271–8285.

Supplementary Information accompanies this paper on the Oncogenesis website (http://www.nature.com/oncsis)